

Donald K Blumenthal

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6517785/publications.pdf>

Version: 2024-02-01

65
papers

2,510
citations

186265

28
h-index

189892

50
g-index

68
all docs

68
docs citations

68
times ranked

1860
citing authors

#	ARTICLE	IF	CITATIONS
1	Defective internal allosteric network imparts dysfunctional ATP/substrate-binding cooperativity in oncogenic chimera of protein kinase A. <i>Communications Biology</i> , 2021, 4, 321.	4.4	21
2	Covalent inhibition of hAChE by organophosphates causes homodimer dissociation through long-range allosteric effects. <i>Journal of Biological Chemistry</i> , 2021, 297, 101007.	3.4	8
3	Rational design, synthesis, and evaluation of uncharged, bis-oxime antidotes of organophosphate-inhibited human acetylcholinesterase. <i>Journal of Biological Chemistry</i> , 2020, 295, 4079-4092.	3.4	24
4	Multi-state recognition pathway of the intrinsically disordered protein kinase inhibitor by protein kinase A. <i>ELife</i> , 2020, 9, .	6.0	16
5	A new crystal form of human acetylcholinesterase for exploratory room-temperature crystallography studies. <i>Chemico-Biological Interactions</i> , 2019, 309, 108698.	4.0	82
6	Productive reorientation of a bound oxime reactivator revealed in room temperature X-ray structures of native and VX-inhibited human acetylcholinesterase. <i>Journal of Biological Chemistry</i> , 2019, 294, 10607-10618.	3.4	13
7	An N-terminally truncated form of cyclic GMP-dependent protein kinase β (PKG β) is monomeric and autoinhibited and provides a model for activation. <i>Journal of Biological Chemistry</i> , 2018, 293, 7916-7929.	3.4	11
8	Differential gene expression patterns in vein regions susceptible versus resistant to neointimal hyperplasia. <i>Physiological Genomics</i> , 2018, 50, 615-627.	2.3	4
9	The Effect of Organophosphate (OP)-Induced Structural Changes in Acetylcholinesterase on Kinetics of OP Inhibition and Oxime Reactivation. <i>FASEB Journal</i> , 2018, 32, 526.40.	0.5	0
10	Impact of Organophosphate (OP) Conjugation on Structure and Dynamics of Human Acetylcholinesterase. <i>FASEB Journal</i> , 2018, 32, 527.8.	0.5	0
11	Dynamics of Organophosphate-Induced Structural Changes in Acetylcholinesterase Revealed by Time-Resolved Small-Angle X-Ray Scattering and Inelastic Neutron Scattering. <i>FASEB Journal</i> , 2018, 32, 527.7.	0.5	0
12	Structure of a PKA R112 Recurrent Acrodysostosis Mutant Explains Defective cAMP-Dependent Activation. <i>Journal of Molecular Biology</i> , 2016, 428, 4890-4904.	4.2	19
13	Limitations in current acetylcholinesterase structure-based design of oxime antidotes for organophosphate poisoning. <i>Annals of the New York Academy of Sciences</i> , 2016, 1378, 41-49.	3.8	17
14	The PKA regulatory subunit from yeast forms a homotetramer: Low-resolution structure of the N-terminal oligomerization domain. <i>Journal of Structural Biology</i> , 2016, 193, 141-154.	2.8	7
15	Prevention of Venous Neointimal Hyperplasia by a Multitarget Receptor Tyrosine Kinase Inhibitor. <i>Journal of Vascular Research</i> , 2015, 52, 244-256.	1.4	6
16	Aberrant Soluble Epoxide Hydrolase and Oxylipin Levels in a Porcine Arteriovenous Graft Stenosis Model. <i>Journal of Vascular Research</i> , 2014, 51, 269-282.	1.4	1
17	The Roles of the R112 Linker and N-terminal Cyclic Nucleotide-binding Domain in Determining the Unique Structures of the Type II β Protein Kinase A. <i>Journal of Biological Chemistry</i> , 2014, 289, 28505-28512.	3.4	5
18	PKA R112 Homodimer Structure Reveals an Intermolecular Interface with Implications for Cooperative cAMP Binding and Carney Complex Disease. <i>Structure</i> , 2014, 22, 59-69.	3.3	37

#	ARTICLE	IF	CITATIONS
19	A kinase interacting protein (AKIP1) is a key regulator of cardiac stress. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, E387-96.	7.1	33
20	Board 391 - Research Abstract Development and Construct Validation of the Interprofessional Attitudes Scale (IPAS) for Assessing the Impact of Interprofessional Simulations (Submission #1233). Simulation in Healthcare, 2013, 8, 571-572.	1.2	1
21	Localization and quaternary structure of the PKA R112 holoenzyme. Proceedings of the National Academy of Sciences of the United States of America, 2012, 109, 12443-12448.	7.1	54
22	In vivo evaluation of the delivery and efficacy of a sirolimus-laden polymer gel for inhibition of hyperplasia in a porcine model of arteriovenous hemodialysis graft stenosis. Journal of Controlled Release, 2012, 160, 459-467.	9.9	29
23	Resolving the structure of Bcy1, the Regulatory Subunit of Yeast Protein Kinase A. FASEB Journal, 2012, 26, 768.3.	0.5	0
24	PDGF-induced proliferation in human arterial and venous smooth muscle cells: Molecular basis for differential effects of PDGF isoforms. Journal of Cellular Biochemistry, 2011, 112, 289-298.	2.6	59
25	Proteins at Work. Journal of Biological Chemistry, 2010, 285, 36121-36128.	3.4	32
26	Sensing Domain Dynamics in Protein Kinase A-112 Complexes by Solution X-ray Scattering. Journal of Biological Chemistry, 2009, 284, 35916-35925.	3.4	21
27	Mechanism of Epac Activation. Journal of Biological Chemistry, 2009, 284, 23644-23651.	3.4	35
28	Longitudinal Assessment of Hyperplasia Using Magnetic Resonance Imaging without Contrast in a Porcine Arteriovenous Graft Model. Academic Radiology, 2009, 16, 96-107.	2.5	17
29	Architecture of the PKA R112 Holoenzyme. FASEB Journal, 2009, 23, 709.11.	0.5	0
30	Cellular and morphological changes during neointimal hyperplasia development in a porcine arteriovenous graft model. Nephrology Dialysis Transplantation, 2007, 22, 3139-3146.	0.7	64
31	Solution Scattering Reveals Large Differences in the Global Structures of Type II Protein Kinase A Isoforms. Journal of Molecular Biology, 2006, 357, 880-889.	4.2	34
32	Mechanism of Dipyridamole's Action in Inhibition of Venous and Arterial Smooth Muscle Cell Proliferation. Basic and Clinical Pharmacology and Toxicology, 2006, 99, 431-439.	2.5	23
33	Efficacy of local dipyridamole therapy in a porcine model of arteriovenous graft stenosis. Kidney International, 2006, 69, 2179-2185.	5.2	31
34	Different signaling responses to anti-proliferative agents in human aortic and venous smooth muscle cells. Journal of Cellular Biochemistry, 2006, 99, 835-844.	2.6	9
35	Differential effects of imatinib on PDGF-induced proliferation and PDGF receptor signaling in human arterial and venous smooth muscle cells. Journal of Cellular Biochemistry, 2006, 99, 1553-1563.	2.6	29
36	Evaluation of histological techniques for quantifying haemodialysis arteriovenous (AV) graft hyperplasia*. Nephrology Dialysis Transplantation, 2006, 21, 3172-3179.	0.7	14

#	ARTICLE	IF	CITATIONS
37	The Conformationally Dynamic C Helix of the R11± Subunit of Protein Kinase A Mediates Isoform-specific Domain Reorganization upon C Subunit Binding. <i>Journal of Biological Chemistry</i> , 2005, 280, 35521-35527.	3.4	21
38	C Subunits Binding to the Protein Kinase A R11± Dimer Induce a Large Conformational Change. <i>Journal of Biological Chemistry</i> , 2004, 279, 19084-19090.	3.4	44
39	Differential Effects of Substrate on Type I and Type II PKA Holoenzyme Dissociation. <i>Biochemistry</i> , 2004, 43, 5629-5636.	2.5	55
40	Conformational Differences Among Solution Structures of the Type I1±, I11± and I11² Protein Kinase A Regulatory Subunit Homodimers: Role of the Linker Regions. <i>Journal of Molecular Biology</i> , 2004, 337, 1183-1194.	4.2	56
41	Isoform Specific Differences in Binding of a Dual-Specificity A-Kinase Anchoring Protein to Type I and Type II Regulatory Subunits of PKA. <i>Biochemistry</i> , 2003, 42, 5754-5763.	2.5	23
42	Common components of patch-clamp internal recording solutions can significantly affect protein kinase A activity. <i>Brain Research</i> , 1999, 828, 169-173.	2.2	26
43	Adaptation of the Protein Kinase Filter Paper Assay to a 96-Well Microtiter Format. <i>Analytical Biochemistry</i> , 1999, 267, 235-238.	2.4	4
44	Troponin I Inhibitory Peptide (96~115) Has an Extended Conformation When Bound to Skeletal Muscle Troponin C. <i>Biochemistry</i> , 1999, 38, 6911-6917.	2.5	23
45	Calmodulin Binding to Myosin Light Chain Kinase Begins at Substoichiometric Ca²+ Concentrations: A Small-Angle Scattering Study of Binding and Conformational Transitions. <i>Biochemistry</i> , 1998, 37, 17810-17817.	2.5	39
46	Antipeptide Antibodies as Probes of Subunit-Dependent Structural Changes in the Regulatory Domain of the Gamma-Subunit of Phosphorylase Kinase. <i>Biochemical and Biophysical Research Communications</i> , 1997, 230, 179-183.	2.1	4
47	Activation and Inhibition of Phosphorylase Kinase by Monospecific Antibodies Raised against Peptides from the Regulatory Domain of the I³-Subunit. <i>Journal of Biological Chemistry</i> , 1996, 271, 21126-21133.	3.4	11
48	Characterization of the Regulatory Domain of the I³-Subunit of Phosphorylase Kinase. <i>Journal of Biological Chemistry</i> , 1995, 270, 22283-22289.	3.4	29
49	Identification of the Substrate and Pseudosubstrate Binding Sites of Phosphorylase Kinase I³-Subunit. <i>Journal of Biological Chemistry</i> , 1995, 270, 7183-7188.	3.4	26
50	Antibody-Mediated Fluorescence Enhancement Based on Shifting the Intramolecular Dimer Monomer Equilibrium of Fluorescent Dyes. <i>Analytical Chemistry</i> , 1994, 66, 1500-1506.	6.5	50
51	Development and characterization of fluorescently-labeled myosin light chain kinase calmodulin-binding domain peptides. <i>Molecular and Cellular Biochemistry</i> , 1993, 127-128, 45-50.	3.1	2
52	Development and characterization of fluorescently-labeled myosin light chain kinase calmodulin-binding domain peptides. , 1993, , 45-50.		0
53	Evidence for domain organization within the 61-kDa calmodulin-dependent cyclic nucleotide phosphodiesterase from bovine brain. <i>Biochemistry</i> , 1991, 30, 7931-7940.	2.5	87
54	Synthetic peptides based on the calmodulin-binding domain of myosin light chain kinase inhibit activation of other calmodulin-dependent enzymes. <i>Biochemical and Biophysical Research Communications</i> , 1988, 156, 860-865.	2.1	29

#	ARTICLE	IF	CITATIONS
55	[10] Preparation and properties of the calmodulin-binding domain of skeletal muscle myosin light chain kinase. <i>Methods in Enzymology</i> , 1987, 139, 115-126.	1.0	35
56	Properties of a monoclonal antibody directed to the calmodulin-binding domain of rabbit skeletal muscle myosin light chain kinase. <i>Biochemistry</i> , 1987, 26, 5885-5890.	2.5	11
57	ORGANIZATION OF MYOSIN LIGHT CHAIN KINASE FROM RABBIT SKELETAL MUSCLE. , 1987, , 494-504.		1
58	Identification of the calmodulin-binding domain of skeletal muscle myosin light chain kinase.. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 1985, 82, 3187-3191.	7.1	310
59	Myosin light chain kinases and myosin phosphorylation in skeletal muscle. <i>Advances in Enzyme Regulation</i> , 1985, 23, 123-140.	2.6	50
60	Interaction of calmodulin and a calmodulin-binding peptide from myosin light chain kinase: major spectral changes in both occur as the result of complex formation. <i>Biochemistry</i> , 1985, 24, 8152-8157.	2.5	142
61	Amino acid sequence of an active fragment of rabbit skeletal muscle myosin light chain kinase. <i>Biochemistry</i> , 1985, 24, 6028-6037.	2.5	115
62	Effects of pH, ionic strength, and temperature on activation by calmodulin and catalytic activity of myosin light-chain kinase. <i>Biochemistry</i> , 1982, 21, 2386-2391.	2.5	118
63	Light chain phosphorylation alters the conformation of skeletal muscle myosin. <i>Biochemical and Biophysical Research Communications</i> , 1980, 93, 209-214.	2.1	42
64	Activation of skeletal muscle myosin light chain kinase by calcium(2+) and calmodulin. <i>Biochemistry</i> , 1980, 19, 5608-5614.	2.5	331
65	Regulation of contraction by myosin phosphorylation. <i>Biochemical Pharmacology</i> , 1980, 29, 2537-2543.	4.4	66